Market Place
Sourcing Support
Orchard Therapeutics Announces Data Presentations and Publications
23 Oct 2024 //
GLOBENEWSWIRE
Orchard And Er-Kim Partner For Libmeldy Access In Turkey
07 Oct 2024 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Presentations At SSIEM 2024
28 Aug 2024 //
GLOBENEWSWIRE
Orchard Celebrates Global Progress In Newborn Screening For MLD
28 Jun 2024 //
GLOBENEWSWIRE
Pharming Group uproots angioedema gene therapy collab with Orchard
09 May 2024 //
FIERCE BIOTECH
Pharming uproots angioedema gene therapy collab with Orchard
08 May 2024 //
FIERCE BIOTECH
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
07 May 2024 //
GLOBENEWSWIRE
Orchard`s Gaspar Named To Inaugural TIME100 Health List
03 May 2024 //
GLOBENEWSWIRE
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
20 Mar 2024 //
FIERCE PHARMA
US approves first gene therapy for children with rare genetic disease
19 Mar 2024 //
REUTERS
Orchard Therapeutics Receives FDA Approval of Lenmeldy(atidarsagene autotemcel),
18 Mar 2024 //
GLOBENEWSWIRE
Orchard Announces First Patient Randomized in Registrational Trial of OTL-203
05 Feb 2024 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium
25 Jan 2024 //
GLOBENEWSWIRE
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics
24 Jan 2024 //
GLOBENEWSWIRE
Orchard Receives Swissmedic Approval for Libmeldy in Early-onset MLD
11 Dec 2023 //
GLOBENEWSWIRE
Orchard Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
30 Nov 2023 //
GLOBENEWSWIRE
Orchard Announces Presentation of Additional Positive Data from OTL-203
26 Oct 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
24 Oct 2023 //
GLOBENEWSWIRE
Kyowa Kirin Buys Orchard for Potential $478M as FDA Decision Looms
06 Oct 2023 //
BIOSPACE
Orchard Therapeutics Announces Acceptance of BLA for OTL-200
18 Sep 2023 //
GLOBENEWSWIRE
Orchard Announces Data Comprising the Clinical Package for OTL-200 BLA in MLD
31 Aug 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Completes Submission of BLA for OTL-200 in MLD to U.S. FDA
03 Aug 2023 //
GLOBENEWSWIRE
Orchard Supports Enactment of Newborn Metabolic Screening Act in Illinois
02 Aug 2023 //
GLOBENEWSWIRE
Orchard to Webcast Conference Call of Second Quarter 2023 Financial Results
25 Jul 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Second Closing of Strategic Financing
26 Jun 2023 //
GLOBENEWSWIRE
Orchard Therapeutics to Present at Stifel Genetic Medicines Day
24 May 2023 //
GLOBENEWSWIRE
Orchard Announces Data in Programs Targeting CNS Disorders at ASGCT
19 May 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Presents Data from Research Programs at ASGCT
18 May 2023 //
GLOBENEWSWIRE
Orchard Reports 1Q 2023 FYR Results of Rolling Submission forBLA of OTL-200
15 May 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
03 May 2023 //
GLOBENEWSWIRE
Orchard to Present at Guggenheim Genomic Medicines and Rare Disease Day
30 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Completes ADS Ratio Change
10 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
06 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
03 Mar 2023 //
GLOBENEWSWIRE
Orchard Announces Agreement Enabling Reimbursed Access to Libmeldy
27 Feb 2023 //
GLOBENEWSWIRE
Orchard Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD
24 Feb 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Proposed ADS Ratio Change
10 Feb 2023 //
GLOBENEWSWIRE
Orchard Announces Comprehensive Presence at 19th Annual WORLDSymposium
08 Feb 2023 //
GLOBENEWSWIRE
Orchard Highlights Progress Across HSC Gene Therapy Portfolio
09 Jan 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203
05 Jan 2023 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Promising Early Neurocognitive OTL-201 MPS-IIIA
12 Dec 2022 //
GLOBENEWSWIRE
Swissmedic validates Orchard’s MAA for Libmeldy to treat early-onset
04 Dec 2022 //
PHARMABIZ
Orchard Announces Swissmedic Validation of the Mak Authorization for Libmeldy
01 Dec 2022 //
GLOBENEWSWIRE
Orchard Therapeutics Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
GLOBENEWSWIRE
Orchard Therapeutics to Webcast Conference Call of 3Q 2022 Financial Results
07 Nov 2022 //
GLOBENEWSWIRE
Orchard Announces First Neurocognitive Data from OTL-201 Study
03 Nov 2022 //
GLOBENEWSWIRE
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress
10 Oct 2022 //
GLOBENEWSWIRE
Orchard Announces Multiple Presentations at 2022 SSIEM Annual Symposium
29 Aug 2022 //
GLOBENEWSWIRE
Oxford Biomedica initiates new project with Orchard Therapeutics
26 Jul 2022 //
GLOBENEWSWIRE
Orchard Therapeutics Announces Presentations at ASGCT 2022
10 May 2022 //
GLOBENEWSWIRE
Orchard Tx to Webcast Conference Call of First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Orchard Tx Announces Reimbursement Agreement for MLD Patients in Italy
11 Apr 2022 //
GLOBENEWSWIRE
Orchard once again restructures, shedding gene therapy programs and staff
31 Mar 2022 //
BIOSPACE
Orchard Tx to Webcast Conference Call of Q4 & Fiscal Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Orchard Tx to Present at Multiple Investor Conferences in March 2022
03 Mar 2022 //
GLOBENEWSWIRE
Orchard Therapeutics secures rare agreement on gene therapy coverage
07 Feb 2022 //
HEALTHCAREAFRICA
Orchard Therapeutics Announces Multiple Presentations at WORLDSymposium™ 2022
07 Feb 2022 //
GLOBENEWSWIRE
Orchard Tx Announces Historic Agreement Making Libmeldy Available by NHS England
03 Feb 2022 //
GLOBENEWSWIRE
Orchard`s Long-term Clinical Outcomes with Libmeldy published in The Lancet
21 Jan 2022 //
GLOBENEWSWIRE
